

Reference:	FOI.1587.19
Subject:	Medicinal cannabis
Date of Request:	11 September 2019

Requested

Cannabis-based medicinal products

1a. Numbers of prescriptions (including individual items) for cannabis-based medicines (excluding Sativex) turned down by Drugs & Therapeutic Committees (or equivalents), per NHS Trust within Hywel Dda University Health Board between 01/10/18 - 01/09/2019

1b. Numbers of prescriptions (including individual items) for cannabis-based medicines (excluding Sativex) turned down by Drugs & Therapeutic Committees (or equivalents), per NHS Trust in within Hywel Dda University Health Board by indications (specifically for people living with multiple sclerosis) between 01/10/18 - 01/09/2019

Sativex

2a. Numbers of prescriptions for Sativex (nabiximol) per Trust within Hywel Dda University Health Board from 01/10/18 - 01/09/19

2b. Numbers of prescriptions for Sativex (nabiximol) per Trust within Hywel Dda University Health Board from 01/10/18 - 01/09/19

Response

1. Hywel Dda University Health Board (UHB) confirms no cannabis-based medicines were turned down by Drugs & Therapeutic Committees (or equivalents), by indications (specifically for people living with multiple sclerosis) for the period requested.

Sativex is approved for its licenced indication in multiple sclerosis (MS) by the all Wales Medicines Strategy Group (AWMSG).

2. The UHB confirms the number of prescriptions for Sativex (Nabiximol) for Glangwili General Hospital (GGH) was five (5) and for Witybush General Hospital (WGH) was ten (10) as recorded on the pharmacy system for the period requested.